目的:测定吉非罗齐的体内过程,作出相对生物利用度评价,为临床合理用药提供依据.方法:8名健康受试者交叉口服单剂量古非罗齐片和胶囊后,用HPLC法测定不同时间的血药浓度,经MCPKP软件拟合处理,并计算药物动力学参数.结果:吉非罗齐片和胶囊均符合开放一室模型,T_(max),C_(max),AUC_(0～∞)分别为(1.61±0.49)和(1.66±0.47)h,(37.28±9.71)和(29.97±5.58)μg/ml;(128.48±24.36)和(119.55±19.48)μg/(h·ml).结论:吉非罗齐片剂对胶囊剂的相对生物利用度为107.26%. OBJECTIVE: To determine the in vivo process of gemfibrozil and to make a relative bioavailability evaluation to provide a basis for clinical rational use of drugs.Methods: Eight healthy volunteers were given a single dose of Gufalocin tablets and capsules at the crossover point and determined by HPLC The blood concentration of different time were fitted by MCPKP software and the pharmacokinetic parameters were calculated.RESULTS: Gemfibrozil tablets and capsules were in accordance with the open model of one-compartment model, and the maximal, max, AUC_ (0) ~ (∞) were (1.61 ± 0.49) and (1.66 ± 0.47) h, (37.28 ± 9.71) and (29.97 ± 5.58) μg / ml; ) Conclusion: The relative bioavailability of gemfibrozil tablets to capsules was 107.26%.